肿瘤细胞治疗研究
英文原题：Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.
癌症干细胞（CSCs）在肿瘤发生、进展和复发中起关键作用，凸显了靶向治疗以实现持久缓解的必要性。
癌症干细胞（CSCs）在肿瘤的发生、进展和复发中起着关键作用，这凸显了开发靶向疗法以实现持久缓解的必要性。本综述深入探讨了CSC生物学，强调了通过有限稀释实验所证明的其肿瘤起始潜能，以及其在治疗耐药中的作用。尽管成功的CAR疗法，如抗CD19 CAR T细胞，能够在不直接靶向CSCs的情况下诱导完全缓解，但聚焦于CSCs的CAR策略可能为预防复发提供有前景的途径。我们评估了靶向CSC特异性抗原（包括CD133和GD2）的CAR疗法在临床前和临床环境中的表现，强调了其针对胶质母细胞瘤、乳腺癌及其他恶性肿瘤的有效性。然而，标志物特异性及肿瘤微环境（TME）的抑制等挑战依然存在。未来策略可能包括双靶向和AI驱动的标志物发现，旨在改善CSC的清除并推进个性化癌症免疫治疗。
Cancer stem cells (CSCs) are pivotal in tumor initiation, progression, and relapse, underscoring the need for targeted therapies to achieve lasting responses. This review delves into CSC biology, highlighting their tumor-initiating potential demonstrated through limiting dilution assays and their role in resistance to therapies. Although successful CAR therapies, such as anti-CD19 CAR T-cells, can induce complete responses without directly targeting CSCs, CAR strategies focusing on CSCs may offer promising avenues to prevent recurrence. We assess CAR therapies targeting CSC-specific antigens, including CD133 and GD2, in preclinical and clinical contexts, emphasizing their effectiveness against glioblastoma, breast cancer, and other malignancies. Nevertheless, challenges such as marker specificity and suppression by the tumor microenvironment (TME) persist. Future strategies, which may include dual-targeting and AI-driven marker discovery, aim to improve CSC elimination and advance personalized cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
